🚨BIG news 🚨
The ICR has received the Queen Elizabeth Prize for Higher and Further Education for our groundbreaking radiotherapy research.
This work has improved cancer care worldwide—through advanced techniques, landmark trials, and training the next generation of oncologists.
#QEdPrizes
Sign up for our webinar with @bursturology.bsky.social on Thursday 23 October, 09.00 to hear experts discuss the use of systemic anti-cancer treatment in metastatic prostate cancer and submit questions in advance 👇
www.natcan.org.uk/events/webin...
See you there! @alison-tree.bsky.social
📢 The NPCA State of the Nation Report 2025 is OUT!
Find the report, supplementary documents & provider results here www.natcan.org.uk/reports/npca...
@natcan-news.bsky.social @hqip.bsky.social @prostatecanceruk.bsky.social @alison-tree.bsky.social @nhsengland.bsky.social
Please share!
New comment piece by me & colleagues in @bmj.com on the using health data for research in UK
Processes are so complex and so slow now that less research is happening and we are wasting the enormous potential of the NHS to drive innovation
www.bmj.com/content/390/...
@alison-tree.bsky.social @ccparker.bsky.social #prostatecancer #pcsm
MARS trial schema
Excited to see the MARS trial highlighted here @cihangani.bsky.social @elekta.com @mrlconsortium.bsky.social @momentumstudy.bsky.social
Pleasure to be at the MRI in RT symposium at USZ @mguckenberger.bsky.social Meme of the day goes to Luca Boldrini
We had the SABR bone and nodes workshop today. @uksabr.bsky.social in collaboration with the RCR. Lots of discussion & learning for all within the SABR MDT. Collaboration at its best. Thank you to all those that attended and especially the speakers. @alison-tree.bsky.social @pattydiezh.bsky.social
Happy to share our review on hypo- and ultra-hypofractionation for prostate cancer radiotherapy, just published in Seminars in Radiation Oncology
@alison-tree.bsky.social @harshanigreen.bsky.social
Full-text link:
authors.elsevier.com/a/1lFrI3lXQo...
Fantastic opening plenary at #UKOF25 by @charlesswanton.bsky.social Cancer initiation is not a simple matter of DNA damage from carcinogens. Forget everything you learned before!
💥 Our Transformational Impact Awards are now OPEN! 💥
This call supports our larger-scale research investments covering high-quality discovery science through to translational and clinical research.
Submission deadline: 1pm, 23 September 2025
Apply now 👉 buff.ly/eCSnnCM
We are looking for two exceptional consultant uro-oncologists to come and join our team in Sutton. Please see further details 👇
www.royalmarsden.nhs.uk/current-vaca...
A great opportunity to work in cutting edge #clinicaltrials within a fun multidisciplinary team @notchonctrainees.bsky.social
Great news! If you have an idea for a new radiotherapy trial, please find the email below
Excited to see the HERMES trial results in print www.sciencedirect.com/science/arti...
Small trial but toxicity of 2 fractions looks promising at 24/27 Gy, no GI tox of G2 or higher out to 12 weeks @momentumstudy.bsky.social @icr.ac.uk
What could be better than 5 days in Verona in October, learning about prostate cancer? Comprehensive multidisciplinary programme aimed at oncologists, urologists, radiologists and anyone else involved in treated prostate cancer. Spread the word!
Encouraging data on safety of 5-fraction SBRT for post-prostatectomy recurrence 👇
Don’t forget to register for the annual UK Oncology forum, which is FREE to attend. Breakout sessions covering topics including prostate cancer and radiotherapy, including Dr Ben O’Leary @icr.ac.uk, Dr Rovel Colaco, Dr Katie Spencer and Prof Stefanie Corradini oncology-forum.co.uk/register/
I think it’s too early to say with PACE B, not enough events, population has lower risk of recurrence than FLAME. Have to patiently wait for the 10 year PACE-B outcomes, or higher risk SBRT studies.
Congratulations to Professor Faivre-Finn on the ESTRO Breur award, and using your platform to encourage us all to address gender inequality in academic radiation oncology 👏 #ESTRO25
Congratulations to @montefiored.bsky.social for a great presentation of the ARISTOTLE trial 👏. Always learn a lot from an RCT, sometimes not the things you were expecting to learn #ESTRO2025
Significant benefit to focal boost in prostate cancer out to 10 years in FLAME trial #ESTRO2025 Fifteen percent of men avoid further treatment just due to the boost 🏆
Congratulations @montefiored.bsky.social & team 👏🏽 I remember talking to you in clinic about this as a registrar. Great to see the results and the impact for patients #ESTRO25 @thelancetoncol.bsky.social
Great summary from Piet Ost, summarising what we know about systemic therapy +/- SBRT (and vice versa) in prostate oligomets #ESTRO25
HYPO-RT-PC 10 year data presented at #ESTRO2025. Seven fractions def non-inferior to 39 fractions, suggestion that 7 fractions might even be more likely to cure?
Exciting data presented in ESTRO 2025 plenary: 5 fraction adjuvant breast RT (26 Gy) at least as good (and possibly better?) than 15 fractions @icr.ac.uk #ESTRO2025
⚠️ Another key finding of this study is that higher rates of metastatic prostate cancer were seen in regions with lower rates of prostate cancer diagnosis overall which may be linked to variation in the use of PSA testing.
#Radonc representation on @NCCN Treatment Guideline Committees is <10%, even for committees that recommend #radiation.
Additionally, certain institutions have nominated relatively few ☢️👩⚕️ for their designated slots.
Glad to see this 📰 finally published.
www.advancesradonc.org/article/S245...
Impt paper from @npca-natcan.bsky.social-geographic variation in prostate cancer diagnosis bmjoncology.bmj.com/content/4/1/... Areas with the HIGHEST risk of metastatic disease have the LOWEST incidence of all prostate cancer. Prostate cancer is curable if caught early @prostatecanceruk.bsky.social
The absolute callousness of announcing a 44% trade tariff against Myanmar this week, of all weeks.